GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zenith Capital Corp (OTCPK:ZHCLF) » Definitions » Dividend Yield %

Zenith Capital (Zenith Capital) Dividend Yield % : 0.00% (As of Jun. 04, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Zenith Capital Dividend Yield %?

As of today (2024-06-04), the Trailing Annual Dividend Yield of Zenith Capital is 0.00%.

The historical rank and industry rank for Zenith Capital's Dividend Yield % or its related term are showing as below:

ZHCLF's Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.58
* Ranked among companies with meaningful Dividend Yield % only.

Zenith Capital's Dividend Payout Ratio for the three months ended in . 20 was 0.00.

As of today (2024-06-04), the Forward Dividend Yield % of Zenith Capital is 0.00%.

Zenith Capital's Dividends per Share for the three months ended in . 20 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.


Zenith Capital Dividend Yield % Historical Data

The historical data trend for Zenith Capital's Dividend Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zenith Capital Dividend Yield % Chart

Zenith Capital Annual Data
Trend
Dividend Yield %

Zenith Capital Quarterly Data
Dividend Yield %

Competitive Comparison of Zenith Capital's Dividend Yield %

For the Biotechnology subindustry, Zenith Capital's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zenith Capital's Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zenith Capital's Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Zenith Capital's Dividend Yield % falls into.



Zenith Capital Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.


Zenith Capital  (OTCPK:ZHCLF) Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.


Zenith Capital Dividend Yield % Related Terms

Thank you for viewing the detailed overview of Zenith Capital's Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Zenith Capital (Zenith Capital) Business Description

Traded in Other Exchanges
N/A
Address
300, 4820 RIchard Road SW, Calgary, AB, CAN, T3E 6L1
Website
Zenith Capital Corp is a biotechnology investment company. The company operates through its wholly-owned subsidiary Zenith Epigenetics Ltd. It is a clinical-stage biotechnology company focused on discovering and developing novel therapeutics. The company is developing various novel combinations of BET inhibitors with other targeted agents. Its lead compound, ZEN-3694, is in clinical development for metastatic Castration Resistant Prostate Cancer (mCRPC) in collaboration with Astellas and Newsoara and in metastatic triple-negative breast cancer.

Zenith Capital (Zenith Capital) Headlines

No Headlines